Prescribing Guides
Telmisartan Prescribing Guide for Indian Clinical Practice
Telmisartan prescribing guide for Indian clinicians covering its unique 24-hour coverage, PPAR-gamma activation, metabolic benefits and NEET PG points.
MedNext Editorial Team | 2026-08-01 | 8 min read
Telmisartan Prescribing Guide for Indian Clinical Practice
Telmisartan prescribing guide for Indian clinicians covering its unique 24-hour coverage, PPAR-gamma activation, metabolic benefits and NEET PG points.
Telmisartan is one of the most prescribed ARBs in India, favoured for its long duration of action, metabolic benefits, and robust clinical trial evidence. It offers true 24-hour blood pressure control with once-daily dosing.
Clinical Pharmacology Overview
Telmisartan is a non-peptide angiotensin II type 1 receptor blocker with the highest lipophilicity and the longest half-life among ARBs. It also acts as a partial PPAR-gamma agonist, conferring potential insulin-sensitising and lipid-modulating properties beyond its antihypertensive effect.
Pharmacokinetics: Bioavailability is dose-dependent (42% at 40 mg, 58% at 160 mg). Highly protein-bound (more than 99.5%). Not metabolised by CYP enzymes -- eliminated primarily by biliary excretion as the unchanged drug. Half-life is approximately 24 hours (the longest among ARBs). No active metabolites.
Indian Brand Names
- Telma (Glenmark)
- Telmikind (Mankind Pharma)
- Telvas (Aristo Pharmaceuticals)
- Telsartan (Sun Pharma)
- Cresar (Cipla)
Approved Indications in Indian Clinical Practice
- Hypertension (monotherapy or combination)
- Cardiovascular risk reduction in patients unable to take ACE inhibitors (ONTARGET data)
- Diabetic nephropathy (extrapolated from ARB class evidence)
Dosing in Adults
Hypertension: Start 20-40 mg once daily. Usual dose: 40-80 mg once daily. Maximum: 80 mg once daily.
Cardiovascular protection: 80 mg once daily (ONTARGET dose).
Can be taken at any time of day, with or without food.
Fixed-dose combinations commonly available in India: telmisartan + amlodipine, telmisartan + hydrochlorothiazide, telmisartan + chlorthalidone, telmisartan + metoprolol.
Important Drug Interactions
- Potassium-sparing diuretics, potassium supplements: hyperkalaemia risk
- ACE inhibitors, aliskiren: avoid dual RAAS blockade
- NSAIDs: reduce antihypertensive efficacy and increase renal risk
- Lithium: increased lithium levels
- Digoxin: telmisartan may increase digoxin levels (monitor)
- Minimal CYP interactions due to non-CYP elimination (an advantage over losartan)
Side Effects and Monitoring
Common: dizziness, headache, upper respiratory infection, back pain. Overall tolerability is excellent.
Serious: hyperkalaemia, renal impairment (bilateral renal artery stenosis), angioedema (very rare).
No dry cough (unlike ACE inhibitors).
Monitoring: serum potassium and creatinine at baseline and periodically. Blood pressure. Renal function monitoring especially important when combined with diuretics or NSAIDs.
Special Populations
Pregnancy: Category D (second and third trimesters). Contraindicated in pregnancy -- all ARBs carry foetotoxicity risk.
Renal impairment: No dose adjustment needed (biliary elimination). Safe in renal impairment. Monitor potassium.
Hepatic impairment: Contraindicated in severe hepatic impairment and biliary obstruction. Use cautiously in mild impairment; do not exceed 40 mg daily.
Elderly: No dose adjustment. Well tolerated in elderly patients.
NEET PG High-Yield Points
- Longest half-life among ARBs (~24 hours) -- true 24-hour BP control
- Highest lipophilicity among ARBs -- better tissue penetration
- Partial PPAR-gamma agonist -- insulin-sensitising property unique among ARBs
- Not metabolised by CYP enzymes -- fewer drug interactions
- No active metabolites (unlike losartan)
- ONTARGET trial: non-inferior to ramipril for CV protection
- Biliary elimination -- no renal dose adjustment but caution in liver disease
- Category D in pregnancy
- Trough-to-peak ratio close to 1 (consistent BP control)
Indian Regulatory Status
Telmisartan is a Schedule H drug under the Drugs and Cosmetics Act. It is included in the NLEM of India and is price-controlled under DPCO. India is a major global manufacturer of telmisartan, and it is one of the most affordable ARBs available. Multiple fixed-dose combinations are marketed and are widely prescribed in cardiology and general practice.
Frequently Asked Questions
Why is telmisartan popular in India?
Telmisartan has the longest half-life among ARBs (approximately 24 hours), providing true 24-hour blood pressure control including the critical early morning surge period. It also activates PPAR-gamma, offering potential metabolic benefits in the high-diabetes Indian population. It is affordable and widely manufactured domestically.
What is the PPAR-gamma effect of telmisartan?
Telmisartan partially activates PPAR-gamma (peroxisome proliferator-activated receptor gamma), which improves insulin sensitivity and has favourable effects on lipid metabolism. This distinguishes it from other ARBs and may offer additional benefit in patients with metabolic syndrome, though clinical outcome data on this mechanism alone is limited.
How does telmisartan compare to ramipril?
The ONTARGET trial showed telmisartan was non-inferior to ramipril for cardiovascular protection in high-risk patients, with fewer side effects (less cough, less angioedema). Telmisartan is a suitable alternative for patients who cannot tolerate ACE inhibitors.
Is telmisartan safe in liver disease?
Telmisartan is primarily eliminated by biliary excretion with no renal dose adjustment needed. However, in significant hepatic impairment, drug levels can increase substantially. It should be used with caution in mild hepatic impairment and is contraindicated in severe hepatic disease or biliary obstruction.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides